Detalhe da pesquisa
1.
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Nature
; 559(7712): 125-129, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29950729
2.
Electrophilic properties of itaconate and derivatives regulate the IκBζ-ATF3 inflammatory axis.
Nature
; 556(7702): 501-504, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29670287
3.
Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Drug Metab Dispos
; 49(10): 870-881, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34321251
4.
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.
Blood
; 125(2): 296-303, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25398940
5.
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
J Med Chem
; 65(6): 4600-4615, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293760
6.
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion.
J Med Chem
; 64(8): 4430-4449, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33829783
7.
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Cancer Cell
; 39(2): 209-224.e11, 2021 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33450196
8.
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
Mol Cancer Ther
; 19(12): 2502-2515, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33082276
9.
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Blood Adv
; 4(9): 1894-1905, 2020 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32380538
10.
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
ACS Med Chem Lett
; 11(2): 101-107, 2020 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32071674
11.
Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase.
Nat Commun
; 10(1): 97, 2019 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30626872
12.
A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition.
Nat Commun
; 10(1): 96, 2019 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30626880
13.
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
J Med Chem
; 51(5): 1145-9, 2008 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-18260618
14.
Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.
Bioorg Med Chem Lett
; 18(6): 2067-72, 2008 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18282707
15.
Tetrazole based amides as growth hormone secretagogues.
Bioorg Med Chem Lett
; 18(8): 2536-9, 2008 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18378446
16.
Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180).
J Med Chem
; 50(24): 5890-3, 2007 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-17973363
17.
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
Cancer Discov
; 7(5): 478-493, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28193778
18.
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Cell Rep
; 15(3): 574-587, 2016 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27068473
19.
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
J Med Chem
; 48(15): 5025-37, 2005 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-16033281
20.
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
J Med Chem
; 48(6): 2248-50, 2005 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-15771468